Literature DB >> 8700557

Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.

D K Moscatello1, R B Montgomery, P Sundareshan, H McDanel, M Y Wong, A J Wong.   

Abstract

An amino-truncated variant form of the epidermal growth factor receptor (EGFRvIII) has been identified in human brain, breast, lung and ovarian tumors. We have found that overexpression of this mutant EGF receptor in NIH3T3 cells results in transformation as a result of the activation of the receptor kinase via ligand-independent dimerization. Transformation was correlated with tyrosine phosphorylation of only a subset of the proteins observed in cells overexpressing the normal EGF receptor. This suggested that further studies on cells expressing the EGFRvIII might provide insights into the pathways most relevant to transformation. In clones expressing high levels of mutant EGF receptor, the levels of both Grb2 and SHC were decreased. Despite this decrease, much of the endogenous Grb2 immunoprecipitated with EGFRvIII. Interestingly, no increase in ras-GTP loading was found in clones expressing the EGFRvIII and MAP kinase assays indicated only a small increase in activity. These results indicate that high-level expression of the EGFRvIII induces down-regulation of the ras-MAP kinase pathway and that other components involved in EGF receptor signal transduction may play a greater role in neoplastic transformation by the EGFRvIII.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700557

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

Review 1.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments.

Authors:  Y Waerzeggers; P Monfared; T Viel; A Faust; K Kopka; M Schäfers; B Tavitian; A Winkeler; A Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

Authors:  Yi Zhan; George J Counelis; Donald M O'Rourke
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

3.  Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Authors:  Christopher M Furcht; Janine M Buonato; Nicolas Skuli; Lijoy K Mathew; Andrés R Muñoz Rojas; M Celeste Simon; Matthew J Lazzara
Journal:  J Cell Sci       Date:  2014-06-20       Impact factor: 5.285

Review 4.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors.

Authors:  E C Piccione; T J Lieu; C F Gentile; T R Williams; A J Connolly; A K Godwin; A C Koong; A J Wong
Journal:  Oncogene       Date:  2011-10-10       Impact factor: 9.867

Review 6.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

Review 7.  Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.

Authors:  Gur Pines; Wolfgang J Köstler; Yosef Yarden
Journal:  FEBS Lett       Date:  2010-04-11       Impact factor: 4.124

8.  Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.

Authors:  D M O'Rourke; G D Kao; N Singh; B W Park; R J Muschel; C J Wu; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

Authors:  Li Li; Amalia Dutra; Evgenia Pak; Joseph E Labrie; Rachel M Gerstein; Pier Paolo Pandolfi; Larry D Recht; Alonzo H Ross
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

10.  Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.

Authors:  David R Emlet; Puja Gupta; Marina Holgado-Madruga; Catherine A Del Vecchio; Siddhartha S Mitra; Shuang-Yin Han; Gordon Li; Kristin C Jensen; Hannes Vogel; Linda Wei Xu; Stephen S Skirboll; Albert J Wong
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.